Can a sleep medicine also help keep bipolar episodes away?
Possibly: there is some evidence that the sleep medicine ramelteon reduces later lows in relatively well adults with bipolar I, which includes severe highs (see Bipolar I and II).
Ramelteon acts like melatonin, a hormone involved in signalling the body's night. The preparation studied matters, and evidence for preventing episodes with other sleep medicines is thinner. Some medicines have well-established benefits for insomnia, difficulty falling or staying asleep despite the chance to sleep, but easier sleep and fewer bipolar episodes need separate evidence. Other sleep medicines can leave the body physically used to the medicine or bring dangerous activity while partly asleep, so the treatment aim and risks need weighing for the particular medicine.1,2,3,4
Whether the medicine helps nights
Zolpidem is a sleep medicine studied for general insomnia. Trials of its extended-release form, which releases the medicine over several hours, found sleep benefits over weeks and in longer studies using people's reports. It is used for short-term insomnia. A useful review checks both whether sleep is easier and whether sleepiness or other effects make the next day harder.1
Bipolar-specific research is less clear. A small study of a medicine for insomnia called suvorexant, involving thirty-six people, found similar reported sleep duration with the medicine and a pill without active medicine, with a modest improvement in measured sleep depending on how it was calculated. Another small study found improved sleep and activity patterns with melatonin in nineteen relatively well people whose sleep timing was unusually late; mood benefit was left unmeasured. These findings are most useful for considering a particular sleep difficulty rather than expecting the same benefit for everyone.3
Whether it also keeps episodes away
A review of ramelteon found fewer returning lows in two trials involving 705 relatively well adults with bipolar I who continued their existing treatment. The combined estimate suggested about a third lower risk of a low compared with the dummy-pill groups, with uncertainty about the size of that benefit. Rates of returning highs and mixed episodes, which bring high and low symptoms together, and reported sleep quality, were similar overall.2
This is some evidence for prevention, with an important practical qualification: the larger trial used a form dissolved under the tongue that the review described as unapproved, while the smaller trial used ordinary tablets. All three ramelteon trials in the review were industry funded. The finding therefore needs careful discussion around the preparation actually available and the person's treatment aim.2
Agreeing the aim and an ending plan
A medicine discussion can separate three aims: easier nights, better next-day functioning and protection against another episode. The person and prescriber, the professional responsible for the prescription, can agree what benefit to look for, how long to try it and how stopping will work. Working out whether sleep medicine fits explains taking the particular medicine.
Benzodiazepines, a group of medicines used for anxiety and sleep, and related sleep medicines such as zolpidem can cause dependence, when the body becomes used to the medicine, and withdrawal symptoms when it is reduced or stopped. These can occur even during recommended short use; stopping after regular use needs an agreed plan.4
Zolpidem can also cause dangerous activity while partly asleep, such as sleepwalking or driving, which needs immediate medical advice if it occurs. The United States label directs stopping zolpidem immediately if such activity happens.1
If sleeping less comes with unusually high energy rather than tiredness, help with the possible high is useful because settling the mood episode becomes part of restoring sleep. What helps when becoming high explains the next steps.
Sources
- 1AMBIEN CR® (zolpidem tartrate) extended-release tablets, for oral use, C-IV Medicine label
- 2Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials Review
- 3Managing Sleep in Bipolar Disorder: An Overview of Pharmacological and Non‐Pharmacological Interventions Sleep-treatment review
- 4Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs UK government
Last updated 12 October 2026
